Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2024 PBAC meeting
15 November 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2024 PBAC ...
Posted by Michael Wonder on 01 Nov 2024
Public Summary Documents – July 2024 PBAC meeting
1 November 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2024 PBAC ...
Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
Posted by Michael Wonder on 01 Oct 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - May 2024 PBAC meeting
1 October 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the May 2024 PBAC ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 11 Sep 2024
Final reports of the HTA Policy and Methods Review and Enhanced Consumer Engagement Process
10 September 2024 - The reports of the HTA Review and the Enhanced Consumer Engagement Process have been published. ...
Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
Posted by Michael Wonder on 30 Aug 2024
Public Summary Documents – May 2024 PBAC meeting
30 August 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2024 PBAC ...
Posted by Michael Wonder on 19 Jul 2024
Public Summary Documents (first time decisions not to recommend and deferrals) - March 2024 PBAC meeting
19 July 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2024 ...
Posted by Michael Wonder on 19 Jul 2024
DUSC utilisation analysis public release documents (June 2024)
19 July 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...
Posted by Michael Wonder on 19 Jul 2024
Outcome statement - June 2024 DUSC meeting
19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available. ...
Posted by Michael Wonder on 10 Jul 2024
Updates to the HTA Policy and Methods Review
10 July 2024 - The Health Technology Assessment (HTA) Policy and Methods Review concluded on 4 May 2024. The HTA ...
Posted by Michael Wonder on 05 Jul 2024
Public Summary Documents – March 2024 PBAC meeting (round 1)
5 July 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2024 PBAC ...
Posted by Michael Wonder on 02 Jul 2024
ICER publishes evidence report on treatment for anaemia in myelodysplastic syndrome
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
Posted by Michael Wonder on 31 May 2024
Annual report highlights progress in science, medicines and health in 2023
30 May 2024 - EMA’s annual report 2023 published today details the Agency’s contributions to public and animal health in the ...